Transgene SA (TNG)

Profile

https://www.transgene.fr

Transgene SA is a French clinical-stage biotechnology company specializing in the development of virus-based immunotherapies for cancer and infectious diseases. Headquartered in Illkirch-Graffenstaden near Strasbourg and founded in 1979, it harnesses viral vector technologies to engineer treatments that stimulate the immune system against tumors or pathogens. Key platforms include the myvac® system, which employs AI to create personalized neoantigen vaccines using Modified Vaccinia Ankara viruses targeting patient-specific tumor mutations, and the Invir.IO platform for oncolytic viruses that selectively replicate in and destroy cancer cells while releasing anti-tumor agents. Its pipeline features promising candidates like TG4050 in Phase I/II trials for head and neck cancer adjuvant therapy, TG4001 for HPV-positive cancers, and oncolytic agents TG6050 and BT-001, bolstered by partnerships such as with AstraZeneca. Transgene SA advances personalized oncology approaches, contributing to innovative therapeutic vaccines and oncolytic therapies that address unmet needs in immunotherapy. As part of the Institut Mérieux, it emphasizes research in tumor microenvironments, immune biomarkers, and preclinical models to propel candidates toward clinical success.